Catherine M. Bonuccelli - 09 Nov 2026 Form 4 Insider Report for IRulya Therapeutics Inc. (IRLA)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Nov 2026, 16:10:07 UTC
Prior SEC filing
19 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John Militello, Attorney-in-Fact
Filing notes and source

Key filing fact

Catherine M. Bonuccelli filed Form 4 for IRulya Therapeutics Inc. (IRLA) on 12 Nov 2026.

Key facts

  • This page summarizes Catherine M. Bonuccelli's Form 4 filing for IRulya Therapeutics Inc. (IRLA).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 12 Nov 2026, 16:10.

Change

  • Previous filing in this sequence was filed on 19 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002159407 Primary reporting owner

Bonuccelli Catherine M.

Relationship
Director
Address
C/O IRULYA THERAPEUTICS INC., 101 COLLEGE STREET, SUITE 210, NEW HAVEN
Signature
/s/ John Militello, Attorney-in-Fact
Signature date
12 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRLA transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
Shares
+17,000
Change %
Price
$0.000000*
Shares after
17,000
Date
09 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
17,000
Exercise price
$33.78
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Beginning October 8, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Issuer's 2026 Equity Incentive Plan) with the Issuer as of each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .